Zacks Research Issues Positive Estimate for AbbVie Earnings

AbbVie Inc. (NYSE:ABBV) – Investment analysts at Zacks Research boosted their Q4 2025 EPS estimates for shares of AbbVie in a research note issued to investors on Friday, November 21st. Zacks Research analyst Team now expects that the company will earn $3.35 per share for the quarter, up from their previous estimate of $3.33. The consensus estimate for AbbVie’s current full-year earnings is $12.31 per share.

Several other equities analysts also recently weighed in on ABBV. Daiwa America raised AbbVie from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 7th. Daiwa Capital Markets upgraded shares of AbbVie from a “neutral” rating to an “outperform” rating and set a $214.00 price objective on the stock in a research report on Thursday, August 7th. Weiss Ratings reissued a “hold (c)” rating on shares of AbbVie in a research note on Wednesday, October 8th. Berenberg Bank raised shares of AbbVie from a “hold” rating to a “buy” rating and lifted their price target for the stock from $170.00 to $270.00 in a research note on Wednesday, September 17th. Finally, Wall Street Zen raised shares of AbbVie from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Two analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and ten have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, AbbVie currently has a consensus rating of “Moderate Buy” and an average target price of $241.85.

AbbVie Stock Down 2.8%

NYSE ABBV opened at $229.61 on Monday. AbbVie has a one year low of $164.39 and a one year high of $244.81. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.61 and a current ratio of 0.74. The stock has a 50 day moving average price of $227.05 and a 200-day moving average price of $205.78. The company has a market capitalization of $405.81 billion, a P/E ratio of 109.34, a P/E/G ratio of 1.42 and a beta of 0.50.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, topping analysts’ consensus estimates of $1.77 by $0.09. The business had revenue of $15.78 billion during the quarter, compared to analyst estimates of $15.58 billion. AbbVie had a net margin of 6.45% and a return on equity of 699.66%. The company’s revenue was up 9.1% on a year-over-year basis. During the same period in the prior year, the business posted $3.00 earnings per share. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS.

AbbVie Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be issued a $1.73 dividend. The ex-dividend date is Friday, January 16th. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.0%. AbbVie’s dividend payout ratio (DPR) is presently 524.24%.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. Brighton Jones LLC boosted its stake in shares of AbbVie by 17.4% during the fourth quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock valued at $4,072,000 after purchasing an additional 3,401 shares in the last quarter. Revolve Wealth Partners LLC lifted its holdings in AbbVie by 72.7% during the fourth quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock worth $1,294,000 after buying an additional 3,064 shares during the period. Neo Ivy Capital Management bought a new stake in AbbVie during the 1st quarter valued at $188,000. Spectrum Wealth Counsel LLC increased its holdings in shares of AbbVie by 1.0% in the 1st quarter. Spectrum Wealth Counsel LLC now owns 33,604 shares of the company’s stock valued at $7,041,000 after acquiring an additional 327 shares during the period. Finally, Bedel Financial Consulting Inc. raised its position in shares of AbbVie by 0.5% in the 1st quarter. Bedel Financial Consulting Inc. now owns 12,544 shares of the company’s stock worth $2,628,000 after acquiring an additional 67 shares in the last quarter. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.